On Friday, Shares of Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), surged 2.87% to $17.57.
Momenta Pharmaceuticals, declared the forthcoming presentation of two posters comparing gene expression profiles and additional methods used to show equivalence between GlatopaTM and daily COPAXONE(R) 20 mg (glatiramer acetate injection). The posters will be presented at the 67th AAN Annual Meeting taking place April 18 — 25, 2015 in Washington, D.C.
Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on developing generic versions of complex drugs, biosimilars, and novel therapeutics for oncology and autoimmune diseases.
Shares of CSX Corp. (NYSE:CSX), gained 2.71% to $33.30, during its last trading session.
CSX Corporation, declared first-quarter 2015 net earnings of $442 million, an 11 percent raise from $398 million in the same period last year. The company also generated earnings per share of $0.45, a 13 percent raise from $0.40 per share in the first quarter of 2014.
Revenue in the quarter was $3.0 billion, driven by growth across many of CSX’s markets and an improved pricing environment, partially offset by the influence of low natural gas prices, lower fuel recoveries and the strong U.S. dollar. At the same time, the benefit of lower fuel prices and cost-saving initiatives more than offset higher inflation and volume-related costs in the quarter. As a result, operating income raised by 14 percent to $843 million and the operating ratio improved 330 basis points to 72.2 percent.
The CSX Board of Directors has approved an raise in the quarterly dividend and a new share repurchase program. The 13 percent raise in the dividend, to $0.18 per share, is payable on June 15, 2015 to shareholders of record at the close of business on May 29, 2015. This is the 13th raise in 10 years, representing a 26 percent compound annual growth rate during that time. The new, $2 billion share repurchase program is predictable to be accomplished over the next 24 months. This follows the successful completion of CSX’s previous repurchase plan, during which the company bought back $1 billion worth of shares. Since 2006, CSX has repurchased nearly $9 billion in shares.
CSX Corporation, together with its auxiliaries, provides rail-based transportation services in the United States and Canada. It offers traditional rail services, and transports intermodal containers and trailers.
At the end of Friday’s trade, Shares of Seagate Technology Public Limited Company (NASDAQ:STX), gained 2.63% to $57.43.
Seagate Technology Public Limited, stated financial results for the third quarter of fiscal year 2015 ended April 3, 2015. For the third quarter, the Company stated revenue of about $3.3 billion, gross margin of 28.7%, net income of $291 million and diluted earnings per share of $0.88. On a non-GAAP basis, which excludes the net influence of certain items, Seagate stated gross margin of 28.9%, net income of $357 million and diluted earnings per share of $1.08.
During the third quarter, the Company generated about $374 million in operating cash flow, paid cash dividends of $176 million and repurchased about 12 million ordinary shares for $706 million. Year to date, the Company has returned about $1.4 billion to shareholders in dividend and stock redemptions. Cash, cash equivalents, restricted cash, and short-term investments totaled about $2.6 billion at the end of the quarter.
The Board of Directors has approved a quarterly cash dividend of $0.54 per share, which will be payable on May 15, 2015 to shareholders of record as of the close of business on May 1, 2015. The payment of any future quarterly dividends will be at the discretion of the Board and will be dependent upon Seagate’s financial position, results of operations, accessible cash, cash flow, capital requirements and other factors deemed relevant by the Board.
Seagate Technology Public Limited Company designs, manufactures, and sells electronic data storage products in the Asia Pacific, the Americas, and EMEA countries.
Finally, Bristol-Myers Squibb Company (NYSE:BMY), ended its last trade with 2.62% gain, and closed at $65.35.
Bristol-Myers Squibb Company, declared that an open-label, randomized Phase III study evaluating Opdivo (nivolumab) as compared to docetaxel in formerly treated patients with advanced non-squamous non-small cell lung cancer (NSCLC) was stopped early because an assessment conducted by the independent Data Monitoring Committee (DMC) concluded that the study met its endpoint, demonstrating superior overall survival in patients receiving Opdivo contrast to the control arm. The company looks forward to sharing these data with health authorities soon.
CheckMate -057 investigators are being informed of the decision to stop the comparative portion of the trial. Bristol-Myers Squibb is working to ensure that eligible patients will be informed of the opportunity to continue or start treatment with Opdivo in an open-label extension as part of the company’s commitment to providing patient access to Opdivo, and characterizing long-term survival. The company will complete a full evaluation of the final CheckMate -057 data and work with investigators on the future presentation and publication of the results.
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It provides chemically-synthesized drugs or small molecules, and biologics in various therapeutic areas, counting virology comprising human immunodeficiency virus infection (HIV); oncology; neuroscience; immunoscience; and cardiovascular.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
